Alkermes (ALKS) FY Conference June 09, 2025 10:00 AM ET Speaker0 Great. Good morning, everyone. Thanks so much for joining us. I'm really pleased to be joined by Richard Pops, chairman and CEO of Alkermes. Thanks so much, Rich, for joining us. Speaker1 Thanks for having us. Speaker0 Yeah. Maybe before we jump into your commercial business and your pipeline, I can start with a big picture question here. Alkermes has been undergoing this evolution over the last couple years. Maybe just level set for us. What ...

DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neurosc ...

– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles –DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring, including presentations largely related to its psychiatry products LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil). Several of these meetings coincided with Mental He ...

Alkermes plc (ALKS) reported earnings from continuing operations of 13 cents per share for first-quarter 2025, which missed the Zacks Consensus Estimate of 28 cents. The company had reported earnings of 21 cents per share in the year-ago quarter.Alkermes’ total revenues of $306.5 million in the first quarter decreased 12.5% from the year-ago quarter’s level due to lower manufacturing and royalty revenues. The top line also missed the Zacks Consensus Estimate of $317 million. (Find the latest EPS estimates a ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35299 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S ...

Core Insights - Alkermes reported a revenue of $306.51 million for the quarter ended March 2025, reflecting a 12.5% decrease year-over-year [1] - The earnings per share (EPS) was $0.13, down from $0.44 in the same quarter last year, indicating a significant decline [1] - The revenue fell short of the Zacks Consensus Estimate of $316.7 million, resulting in a surprise of -3.22% [1] - The company experienced an EPS surprise of -53.57%, with the consensus EPS estimate being $0.28 [1] Revenue Breakdown - Manufacturing and Royalty revenues were reported at $62.02 million, below the five-analyst average estimate of $65.33 million, marking a year-over-year decline of 46.9% [4] - Product sales, net, amounted to $244.49 million, slightly below the estimated $254.16 million, but showed a year-over-year increase of 4.7% [4] - Proprietary Sales for VIVITROL reached $101 million, exceeding the four-analyst average estimate of $98.71 million, with a year-over-year growth of 3.4% [4] - Proprietary Sales for ARISTADA were reported at $73.50 million, below the estimated $78.52 million, reflecting a year-over-year decrease of 6.8% [4] - Proprietary Sales for LYBALVI were $70 million, close to the estimated $70.91 million, showing a year-over-year increase of 22.8% [4] - Key Commercial Product Revenues for VUMERITY were $27.80 million, slightly below the three-analyst average estimate of $27.81 million, with a year-over-year decline of 11.1% [4] Stock Performance - Alkermes shares have returned -11.9% over the past month, contrasting with the Zacks S&P 500 composite's -0.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Alkermes (ALKS) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.44 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -53.57%. A quarter ago, it was expected that this drugmaker would post earnings of $0.81 per share when it actually produced earnings of $1.04, delivering a surprise of 28.40%.Over the last four quarters, the company has ...

First Quarter 2025 Financial Results & Business Update May 1, 2025 Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations with respect to its current and future financial, commercial and operating performance, business plans or p ...

Alkermes (ALKS) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Speaker0 and welcome to Alchemy's First Quarter twenty twenty five Financial Results Conference Call. My name is Maria, and I'll be the operator for today's call. All participant lines will be placed on mute to prevent background Please note that this conference is being recorded. I will now turn the call over to Sandra Khoemps, Senior Vice President of Investor Relations and Corporate Affairs. Sandy, you may now begin. Good morning. Welcome to ...